エピソード

  • Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

    Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
    2024/10/25
    Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.
    続きを読む 一部表示
    46 分
  • Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors

    Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors
    2024/10/18
    Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.
    続きを読む 一部表示
    59 分
  • Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

    Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
    2024/09/25
    Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.
    続きを読む 一部表示
    50 分
  • Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

    Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
    2024/09/06
    Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
    続きを読む 一部表示
    1 時間 3 分
  • Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    2024/08/29
    Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.
    続きを読む 一部表示
    1 時間 16 分
  • Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer

    Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer
    2024/08/23
    Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.
    続きを読む 一部表示
    46 分
  • Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

    Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
    2024/08/16
    Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.
    続きを読む 一部表示
    54 分
  • Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer

    Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
    2024/08/07
    Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.
    続きを読む 一部表示
    1 時間 15 分